====================================================================================================
DRUG CAUSALITY VERIFICATION REPORT
====================================================================================================
Generated: 2025-11-01 23:59:30
Model: ./models/production_model_final
Threshold: 0.5

====================================================================================================
PDF: fphar-16-1498191.pdf
====================================================================================================
Total Sentences: 415
Related Sentences: 19
Confidence Score: 0.0458
Classification: RELATED

ALL DRUG-EVENT CAUSALITY RELATED SENTENCES:
----------------------------------------------------------------------------------------------------

1. [Sentence #132]
   Adalimumab, commonly used for th e treatment of severe uveitis
associated with juvenile idiopath ic arthritis, has been reported to
contribute to cataracts and glaucoma, leading to signi ﬁcant visual
impairment ( Lu et al., 2021 ;Fleischmann et al., 2022 ).
   Probability: 0.999926
   Confidence: 0.999926

2. [Sentence #130]
   Interferon Beta-1A, indicated for multiple sclerosis, was also
identi ﬁed as potentially associated with drug-induced cataracts.
   Probability: 0.999917
   Confidence: 0.999917

3. [Sentence #118]
   Further research is warranted to elucidate the underlyingmechanisms and explore the epidemiology of bisphosphonate-related cataracts.
   Probability: 0.999901
   Confidence: 0.999901

4. [Sentence #152]
   In the RESONATE phase III
multicenter trial, among approximately 400 patients withrelapsed or refractory chronic lymphocytic leukemia (CLL) or
small lymphocytic lymphoma (SLL) receiving Ibrutinib, 10%
reported blurred vision, and 3% developed cataracts.
   Probability: 0.999878
   Confidence: 0.999878

5. [Sentence #121]
   Our analysis suggests thatesomeprazole may be an independent risk factor for cataracts.However, given the limited current evidence, further large-scaleRCTs are warranted to elucidate this potential risk and assess itsclinical implications comprehensively.
   Probability: 0.999822
   Confidence: 0.999822

6. [Sentence #105]
   Consistent with these ﬁndings, our
multivariate logistic regression anal ysis indicated that atorvastatin may
be an independent risk factor for dr ug-induced cataracts (Odds Ratio
(OR) [95% CI]: 12 [7.6 –18]).
   Probability: 0.999776
   Confidence: 0.999776

7. [Sentence #129]
   Consistently,
our multivariate logistic regression analysis suggested thatRisankizumab may be an independent risk factor for cataracts.However, the precise pathogenic mechanisms remain unclear and
warrant further investigation.
   Probability: 0.999759
   Confidence: 0.999759

8. [Sentence #93]
   Bimatoprost, a prostaglandin analog commonly
prescribed for ocular conditions, may induce cataracts by increasing
melanocyte activity in iris me lanocytes, leading to iris
hyperpigmentation (reported in approximately 7% –16% of patients).
   Probability: 0.999605
   Confidence: 0.999605

9. [Sentence #116]
   The proposed mechanisms suggest that
zoledronic acid may impair eye lens epithelial cell function by inducing
local in ﬂammation and protein denaturati on, ultimately contributing to
cataract formation ( Lee et al., 2020 ).
   Probability: 0.999471
   Confidence: 0.999471

10. [Sentence #78]
   The results identi ﬁed 15 drugs (Bimatoprost, Atorvastatin,
Zoledronic Acid, Esomeprazol e, Risankizumab, Interferon β-1,
Adalimumab, Prednisone, Ibrutini b, Upadacitinib, Tofacitinib,
Sodium Oxybate, Tiotropium, Pomalidomide, and Lenalidomide) as
independent risk factors for dru g-induced cataracts.
   Probability: 0.999273
   Confidence: 0.999273

11. [Sentence #154]
   Additionally, a case report
suggested that Ibrutinib may penetrate the blood-aqueous barrier,altering the ocular microenvironment and causing plateletdysfunction and impaired ﬁbrinolysis, potentially leading to
anterior chamber ﬁbrinoid syndrome following cataract surgery
(Wang et al., 2025 ).
   Probability: 0.999124
   Confidence: 0.999124

12. [Sentence #163]
   Although no direct association between Pomalidomide
and cataracts has been reported, a prospective study involving
vitreoretinal lymphoma patients receiving intravitreal
methotrexate (MTX), Rituximab, and Lenalidomide ( R2regimen)
as maintenance therapy identi ﬁed notable ocular toxicities,
including cataracts, suggesting a potential increase in oculartoxicity risk ( Zhang et al., 2021 ).
   Probability: 0.998523
   Confidence: 0.998523

13. [Sentence #115]
   A study based
on Optum and MarketScan databases reported a potential associationbetween zoledronic acid treatment and an increased risk of cataracts(ROR [95% CI]: 12 [7.6 –18]).
   Probability: 0.998040
   Confidence: 0.998040

14. [Sentence #133]
   However, in
our study, the cataract signal associ ated with Adalimumab may represent
a false positive, potentially in ﬂuenced by underlying diseases or inadequate
treatment responses.
   Probability: 0.997400
   Confidence: 0.997400

15. [Sentence #124]
   Consistently, our multivariate
logistic regression analysis identi ﬁed atorvastatin as an independentrisk factor for drug-induced cataracts (OR [95% CI]: 12 [7.6 –18]).
   Probability: 0.993490
   Confidence: 0.993490

16. [Sentence #134]
   Therefore, further research is necessary to establish adeﬁnitive causal relationship between Adalimumab and cataracts.
   Probability: 0.993086
   Confidence: 0.993086

17. [Sentence #285]
   Risk of
cataract surgery and age-related macular degeneration after initiation of denosumab vs
zoledronic acid for osteoporosis: a multi-database cohort study.
   Probability: 0.991020
   Confidence: 0.991020

18. [Sentence #74]
   According to the analysis, the top ﬁve medications associated
with an increased risk of cataracts were Alendronic Acid (ROR =13.92, 95% CI: 12.51 –15.48, P <0.01), Ibrutinib (ROR = 5.26, 95%
CI: 4.85 –5.70, P <0.01), Upadacitinib (ROR = 4.99, 95% CI:
4.52–5.51, P <0.01), Tiotropium (ROR = 4.36, 95% CI:3.97–4.97, P <0.01), and Adalimumab (ROR = 2.79, 95% CI:
2.65–2.94, P <0.01).
   Probability: 0.977487
   Confidence: 0.977487

19. [Sentence #289]
   Ibrutinib alleviates
LPS-induced neuroin ﬂammation and synaptic defects in a mouse model of depression.
   Probability: 0.972853
   Confidence: 0.972853


====================================================================================================
PDF: zh801708001593.pdf
====================================================================================================
Total Sentences: 454
Related Sentences: 53
Confidence Score: 0.1167
Classification: RELATED

ALL DRUG-EVENT CAUSALITY RELATED SENTENCES:
----------------------------------------------------------------------------------------------------

1. [Sentence #229]
   Bortez-
omib-induced peripheral neurotoxicity: a neuro-physiological and pathological study in the rat.Exp Neurol.
   Probability: 0.999945
   Confidence: 0.999945

2. [Sentence #20]
   5We herein review and discuss the pathogenesis,
incidence, risk factors, diagnosis, characteristics, and managementof bortezomib-induced peripheral neuropathy (BIPN).
   Probability: 0.999930
   Confidence: 0.999930

3. [Sentence #385]
   Cavaletti G, Nobile-Orazio E. Bortezomib-
induced peripheral neurotoxicity: still far from apainless gain.
   Probability: 0.999929
   Confidence: 0.999929

4. [Sentence #307]
   A prospective study ofbortezomib-induced peripheral neuropathy.Neuro-Oncol.
   Probability: 0.999924
   Confidence: 0.999924

5. [Sentence #220]
   Use of immunoglobulin infusions in the man-agement of bortezomib-induced peripheral neu-
ropathy in multiple myeloma.
   Probability: 0.999919
   Confidence: 0.999919

6. [Sentence #241]
   Quantitative sensory ﬁndingsin patients with bortezomib-induced pain.
   Probability: 0.999916
   Confidence: 0.999916

7. [Sentence #84]
   22
One could suggest that treatment schedules consisting of
thalidomide plus bortezomib would lead to increased incidence andseverity of neurotoxicity, because of the well-known neurotoxiceffect both drugs exert.
   Probability: 0.999914
   Confidence: 0.999914

8. [Sentence #21]
   We alsohighlight areas of future research to pursue.Search strategy and selection criteria
References for this review were identiﬁed by searches of
PubMed from 2000 until March 2008 with the terms “pro-teasome inhibitors,” “proteasome inhibitors and peripheral neuro-pathy,” “Velcade,” “bortezomib-induced neurotoxicity,” “bortezomib-induced peripheral neuropathy,” and “chemotherapy-inducedperipheral neuropathy.”
Pathogenesis of peripheral neuropathy
Current knowledge of the mechanism underlying BIPN is verylimited.
   Probability: 0.999914
   Confidence: 0.999914

9. [Sentence #1]
   Review article
Bortezomib-induced peripheral neuropathy in multiple myeloma:
a comprehensive review of the literature
Andreas A. Argyriou,1,2Gregoris Iconomou,2and Haralabos P. Kalofonos2
1Department of Neurology, Saint Andrew’s General Hospital of Patras, Patras; and2Department of Medicine, Division of Oncology, University of Patras Medical
School, Rion-Patras, Greece
Bortezomib has demonstrated signiﬁcant
activity in clinical trials, mainly againstrecurrent or newly diagnosed multiplemyeloma (MM).
   Probability: 0.999869
   Confidence: 0.999869

10. [Sentence #390]
   Features
and risk factors of peripheral neuropathy duringtreatment of advanced multiple myeloma withbortezomib.
   Probability: 0.999850
   Confidence: 0.999850

11. [Sentence #94]
   38,39BORTEZOMIB-INDUCED PERIPHERAL NEUROPATHY 1595 BLOOD, 1 SEPTEMBER 2008 /H18528VOLUME 112, NUMBER 5Downloaded from http://ashpublications.org/blood/article-pdf/112/5/1593/1486876/zh801708001593.pdf by guest on 25 October 2025
According to published data, the incidence of grade 3 or 4
neurotoxicity was 14% for patients aged less than 75 years and25% in older patients, thereby supporting the view that elderlypatients may be more prone than younger patients to manifestingincreased incidence and severity of BIPN.
   Probability: 0.999848
   Confidence: 0.999848

12. [Sentence #131]
   severe distal and proximal weakness QST: Increased touch thresholds, increased slotted pegboard time, cold pain thresholds at
Very rarely, autonomic failure abnormally warm levels and reduction in sharpness detection
BIPN indicates bortezomib-induced peripheral neuropathy; NCS, nerve conduction study; a-SAPs, amplitude of sensory action potentials; CMAPs, co mpound muscle
action potentials; EMG, electromyography; and QST, quantitative sensory testing.1596 ARGYRIOU et al BLOOD, 1 SEPTEMBER 2008 /H18528VOLUME 112, NUMBER 5Downloaded from http://ashpublications.org/blood/article-pdf/112/5/1593/1486876/zh801708001593.pdf by guest on 25 October 2025
(31/256), representing 34% of patients (31/90) who developed
new or worsening neuropathy.
   Probability: 0.999808
   Confidence: 0.999808

13. [Sentence #36]
   13
Finally, results from a neurophysiologic study applying quanti-
tative sensory testing in patients receiving bortezomib for treatmentof either MM or non-Hodgkin lymphoma demonstrated thatbortezomib-induced pain is associated with deﬁcits of all 3 majorﬁber types, ie, A /H9252,A/H9254, and C caliber primary afferent ﬁbers.
   Probability: 0.999798
   Confidence: 0.999798

14. [Sentence #454]
   BORTEZOMIB-INDUCED PERIPHERAL NEUROPATHY 1599 BLOOD, 1 SEPTEMBER 2008 /H18528VOLUME 112, NUMBER 5Downloaded from http://ashpublications.org/blood/article-pdf/112/5/1593/1486876/zh801708001593.pdf by guest on 25 October 2025
   Probability: 0.999796
   Confidence: 0.999796

15. [Sentence #296]
   Peripheral neuropathy induced by administra-tion of cisplatin and paclitaxel-based chemo-therapy.
   Probability: 0.999766
   Confidence: 0.999766

16. [Sentence #224]
   Chaudhry V, Cornblath DR, Corse A, Freimer M,
Simmons-O’Brien E, Vogelsang G. Thalidomide-induced neuropathy.
   Probability: 0.999738
   Confidence: 0.999738

17. [Sentence #148]
   53Table 3 outlines the pharmaceutical
interventions for the symptomatic treatment of bortezomib-inducedneuropathic pain.
   Probability: 0.999730
   Confidence: 0.999730

18. [Sentence #144]
   However, theevidence of clinical improvement is considerable, in contrast withother forms of neurotoxicity in MM patients, especially afterthalidomide treatment.
   Probability: 0.999722
   Confidence: 0.999722

19. [Sentence #408]
   Development of neuropathy inpatients with myeloma treated with thalidomide:patterns of occurrence and the role of electro-physiologic monitoring.
   Probability: 0.999685
   Confidence: 0.999685

20. [Sentence #139]
   19,20,32However, there are reports in which the recovery
from pain and other sensory neuropathic symptoms required up
to 2 years after bortezomib discontinuation.35In a recently
published study, detailed clinical assessment and neurophysi-
ologic examination was performed in 35 patients with advancedMM experiencing grade 3 BIPN after completion of bortezomibtherapy.
   Probability: 0.999677
   Confidence: 0.999677

21. [Sentence #56]
   Incidence, severity, and risk factors
Current knowledge shows that peripheral nerve damage is oneof the most signiﬁcant nonhematologic toxicities of bortezomib,which often leads to dose modiﬁcation and impact on clinicalendpoints and quality of life (QOL) of patients.
   Probability: 0.999644
   Confidence: 0.999644

22. [Sentence #111]
   In a recent study, bortezomib-inducedpain was rated in the majority of patients as moderate to severe,according to V AS.
   Probability: 0.999518
   Confidence: 0.999518

23. [Sentence #320]
   Gupta S, Pagliuca A, Devereux S, Mufti GJ,
Schey S. Life-threatening motor neurotoxicity inassociation with bortezomib.
   Probability: 0.999511
   Confidence: 0.999511

24. [Sentence #165]
   Conclusions and future research
perspectives
Peripheral neuropathy is a common and important nonhematologic,
dose-limiting adverse effect of bortezomib-based chemotherapy,Table 3.
   Probability: 0.999482
   Confidence: 0.999482

25. [Sentence #426]
   Levine S, Saltzman A. Pyridoxine (vitamin B6)
neurotoxicity: enhancement by protein-deﬁcientdiet.
   Probability: 0.999470
   Confidence: 0.999470

26. [Sentence #19]
   4
Peripheral neuropathy (PN) is a signiﬁcant dose-limiting toxic-
ity of bortezomib that typically occurs within the ﬁrst courses ofbortezomib, reaches a plateau at cycle 5, and thereafter does notappear to increase.
   Probability: 0.999436
   Confidence: 0.999436

27. [Sentence #37]
   14In
any case, both the pathogenesis of BIPN and the anatomical
structures that are primarily or secondarily affected by bortezomibare vaguely deﬁned, and further studies are warranted beforedeﬁnite conclusions can be drawn.
   Probability: 0.999361
   Confidence: 0.999361

28. [Sentence #77]
   In the study by Richardson et al,
19treatment-emergent peripheral
neuropathy was reported in 21% of patients receiving bortezomib at a
single dose of 1.0 mg/m2and 37% in patients receiving bortezomib at
1.3 mg/m2.
   Probability: 0.999317
   Confidence: 0.999317

29. [Sentence #80]
   From
a clinical point of view it should be emphasized that BIPN typicallyoccurs within the ﬁrst 5 cycles of bortezomib administration and is rarethereafter, suggesting a dose threshold rather than a classic cumulativedose effect of bortezomib.
   Probability: 0.999194
   Confidence: 0.999194

30. [Sentence #57]
   Grades 1 and 2BIPN can occur in up to 75% and 33% of patients with recurrentor newly diagnosed disease under bortezomib therapy, respec-tively, whereas grades 3 and 4 neurotoxicity may affect up to30% of patients with recurrent disease and up to 18% of patientswith newly diagnosed disease.
   Probability: 0.999150
   Confidence: 0.999150

31. [Sentence #262]
   Frequency, characteristics, and reversibility ofperipheral neuropathy during treatment of ad-vanced multiple myeloma with bortezomib.
   Probability: 0.999086
   Confidence: 0.999086

32. [Sentence #30]
   Bortezomib-induced changes were also observed in dorsal root ganglia (DRG)neurons, being represented by satellite cell intracytoplasmaticvacuolization due to mitochondrial and endoplasmic reticulumdamage.
   Probability: 0.998979
   Confidence: 0.998979

33. [Sentence #9]
   Analgesics, tricyclic antidepres-sants, anticonvulsants, and vitaminsupplements have been used as symp-tomatic treatment against bortezomib-associated neuropathic pain with somesuccess.
   Probability: 0.998889
   Confidence: 0.998889

34. [Sentence #103]
   Peripheral neuropathy at baseline was seen inmore than 20% of patients with newly diagnosed MM scheduled tobe treated with single-agent bortezomib therapy.
   Probability: 0.998471
   Confidence: 0.998471

35. [Sentence #2]
   Peripheral neuropathy isa signiﬁcant toxicity of bortezomib, requir-ing dose modiﬁcation and potentialchanges in the treatment plan when itoccurs.
   Probability: 0.997823
   Confidence: 0.997823

36. [Sentence #311]
   Neu-
ropathy in multiple myeloma patients treated withbortezomib: a multicenter experience.
   Probability: 0.997762
   Confidence: 0.997762

37. [Sentence #71]
   In another interesting report, Badros et al
20retrospectively
reviewed the incidence, severity, and risk factors of BIPN in
78 patients with recurrent and/or refractory MM who were treatedwith bortezomib alone or in combination with thalidomide and/orchemotherapy.
   Probability: 0.997685
   Confidence: 0.997685

38. [Sentence #90]
   In contrast, the use of bortezomib and lenalidomide, an analog
of thalidomide, has been associated with lower accumulated ratesof BIPN.
   Probability: 0.997455
   Confidence: 0.997455

39. [Sentence #176]
   Compared with other neurotoxic drugs in oncology (ie, taxanes,platinums, and thalidomide), work with BIPN has in fact beenintensive, for which some credit to both the investigators and themanufacturer (Millennium Pharmaceuticals, Cambridge, MA), asbortezomib toxicity has been taken very seriously from the earliestphases of bortezomib development.
   Probability: 0.997390
   Confidence: 0.997390

40. [Sentence #51]
   To our knowledge, TNS score has been used in a single study
that assessed BIPN in 27 patients treated with bortezomib andthalidomide for newly diagnosed MM.
   Probability: 0.997358
   Confidence: 0.997358

41. [Sentence #267]
   Neuro-
toxicity of bortezomib therapy in multiple my-eloma: a single-center experience and review ofthe literature.
   Probability: 0.997084
   Confidence: 0.997084

42. [Sentence #100]
   4Current
knowledge, shows that the use of bortezomib in solid malignan-
cies is associated with lower rates of BIPN as opposed whenadministered for MM.
   Probability: 0.996851
   Confidence: 0.996851

43. [Sentence #167]
   However, despite the increasing number ofpatients exposed to bortezomib therapy, there is a relative paucityof data concerning BIPN.
   Probability: 0.996389
   Confidence: 0.996389

44. [Sentence #24]
   This fact supports the view that mitochondrial-mediateddisregulation of Ca
/H11001/H11001homeostasis is a critical regulator of
bortezomib cytotoxicity.7
Disregulation of neurotrophins has also been proposed as
another important mechanism of BIPN genesis, since the mainaction of bortezomib is the inhibition of NF- /H9260B activation, thereby
blocking the transcription of nerve growth factor-mediated neuronsurvival.
   Probability: 0.995965
   Confidence: 0.995965

45. [Sentence #3]
   The mechanism underlyingbortezomib-induced peripheral neuropa-thy (BIPN) is unknown.
   Probability: 0.995423
   Confidence: 0.995423

46. [Sentence #120]
   5
Finally, the neurophysiologic approach with quantitative sen-
sory testing in patients receiving bortezomib reveals increasedtouch thresholds, increased slotted pegboard time, abnormal coldpain thresholds, and reduction in sharpness detection, implying thatBIPN is associated with dysfunction in all 3 major ﬁber types (A /H9252,
A/H9254, and C) in sensory nerves.
   Probability: 0.993453
   Confidence: 0.993453

47. [Sentence #82]
   19,20In addition, a
preliminary report of bortezomib safety in patients with relapsed/
refractory MM indicated that less heavily pretreated patients in anearlier stage of disease manifest milder BIPN.
   Probability: 0.993176
   Confidence: 0.993176

48. [Sentence #83]
   37Prolonged admin -
istration of bortezomib is not signiﬁcantly associated with in-creased incidence and severity of BIPN.
   Probability: 0.992756
   Confidence: 0.992756

49. [Sentence #132]
   In 7% of patients (19/256), atleast one course of bortezomib was withheld because ofperipheral neuropathy, representing 21% of patients (19/90)with new or worsening neuropathy.
   Probability: 0.992536
   Confidence: 0.992536

50. [Sentence #422]
   Levine S, Saltzman A. Pyridoxine (vitamin B6)
toxicity: enhancement by uremia in rats.
   Probability: 0.992327
   Confidence: 0.992327

51. [Sentence #97]
   It has been also reported that BIPN may be associated with
impaired renal function and worst creatinine clearance in patientswith MM.
   Probability: 0.989745
   Confidence: 0.989745

52. [Sentence #153]
   Vitamin B6 can cause additionalsensory neuropathy in patients with impaired renal function and inassociation with a protein-deﬁcient diet.
   Probability: 0.989146
   Confidence: 0.989146

53. [Sentence #232]
   Corsetti G, Rodella L, Rezzani R, Stacchiotti A,
Bianchi R. Cytoplasmic changes in satellite cellsof spinal ganglia induced by cisplatin treatment inrats.
   Probability: 0.988537
   Confidence: 0.988537


